JonesResearch raised the firm’s price target on Monopar Therapeutics (MNPR) to $37 from $9 and keeps a Buy rating on the shares post the Q3 report. The company in October announced a strategic agreement with Alexion, a subsidiary of AstraZeneca (AZN), for the exclusive worldwide in-licensing of ALXN-1840 for the treatment of Wilson’s disease, the analyst tells investors in a research note. The firm added risk-adjusted revenue estimates for ALXN-1840 in Wilson’s disease to its model. Jones assigns a 50% probability of success and estimates a U.S. launch in fiscal 2026. It estimates risk-adjusted ALXN-1840 revenues of $90.6M in fiscal 2038.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $22 from $6 at H.C. Wainwright
- Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)
- Monopar Therapeutics Closes $19.2 Million Stock Offering
- Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25
- Monopar Therapeutics announces common stock offering, no amount given